Business ❯ Biotechnology

Clinical Research

Drug Development Pharmaceuticals Pharmaceutical Companies Therapeutics Immunotherapy Drug Trials Celcuity Inc. Regulatory Affairs Product Development Nanotechnology Regulatory Approval Drug Approval Process Acquisitions Cancer Therapies Drug Efficacy Investor Relations Oncology Cell Therapy Drug Applications PulseSight Therapeutics FDA Designation Cancer Treatment Market Response Market Needs Drug Approval

Amylyx’s Avexitide Cuts Moderate‑to‑Severe Post‑Bariatric Hypoglycemia Events 55% in Phase 3

Amylyx plans a year‑end FDA filing that could lead to a 2027 launch funded by a new equity offering.

ProMIS Reports Blinded Six‑Month Interim Data Showing No ARIA‑E in PMN310 Phase 1b Trial

Theriva’s VCN-01 Extends Survival in Phase 2b Pancreatic Cancer Trial, Paving Way to Phase 3

Atrogi Begins Dosing in 8-Week Human Study of GRK2-Biased β2 Agonist ATR-258

Gilead to Acquire Arcellx for Up to $7.8 Billion to Gain Full Control of CAR-T Anito-Cel

Wave Life Sciences Soars on Obesity Trial Signal as It Begins $250 Million Stock Offering

Exicure’s Burixafor Delivers About 90% Stem-Cell Mobilization in Phase 2 as Shares Surge

Protara Reports Strong Interim Phase 2 Results for TARA-002 in Pediatric Lymphatic Malformations

Rapport Seizure Drug Posts Strong Phase 2 Signal as Company Plans Phase 3